A simplified strategy for clinical management of late cytomegalovirus infection after oral ganciclovir prophylaxis in renal recipients

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 3, 2005, Pages 391-394

  Kuypers, Dirk R J ^a   Claes, Kathleen ^a   Evenepoel, Pieter ^a   Maes, Bart ^a   Vanrenterghem, Yves ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

CMV disease; CMV infection; CMV monitoring; CMV prophylaxis; Kidney transplantation

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; VIRUS DNA;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; CHRONIC GRAFT REJECTION; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; GRAFT FAILURE; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PREDICTION; PROSPECTIVE STUDY; RECIPIENT; RISK ASSESSMENT;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES;

EID: 15844430649     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki031     Document Type: Article

References (13)

1. Evans, P. C., Soin, A., Wreghitt, T. G. et al. (2000). An association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation 69, 30-5.
2. Gorensek, M. J., Stewart, R. W., Keys, T. F. et al. (1988). Symptomatic cytomegalovirus infection as a significant risk factor for major infections after cardiac transplantation. Journal of Infectious Diseases 158, 884-7.
3. Fitzgerald, J. T., Gallay, B., Taranto, S. E. et al. (2004). Pretransplant recipient cytomegalovirus seropositivity and hemodialysis are associated with decreased renal allograft and patient survival. Transplantation 77, 1405-11.
4. Yango, A., Morrissey, P., Zanabli, A. et al. (2003). Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients. Nephrology Dialysis Transplantation 18, 809-13.
5. Reischig, T., Opatrny, K., Jr, Bouda, M. et al. (2002). A randomised prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. Transplant International 15, 615-22.
6. Lowance, D., Neumayer, H. H., Legendre, M. et al. (1999). Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. New England Journal of Medicine 340, 1462-70.
7. Clark, B. S., Chang, I. F., Karpen, S. J. et al. (2004). Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients. Transplantation 77, 1480.
8. Paya, C., Humar, A., Dominguez, E. et al. (2004). Efficacy and safety of valganciclovir vs. oral gahciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. American Journal of Transplantation 4, 611-20.
9. Valantine, H. A., Gao, S. Z., Menon, S. G. et al. (1999). Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomised, placebo-controlled study. Circulation 100, 61-6.
10. Singh, N. (2001). Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clinical Infectious Diseases 32, 742-51.
11. Brennan, D. C., Garlock, K. A., Singer, G. G. et al. (1997). Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 64 1843-6.
12. Murray, B. M. & Subramaniam, S. (2004). Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients. Transplant Infectious Disease 6, 3-9.
13. Emery, V. C., Sabin, C. A., Cope, A. V. et al. (2000). Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355, 2032-6.